{"disease":{"id":"precursor-b-cell-acute-lymphoblastic-leukemia","name":"precursor b cell acute lymphoblastic leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07134088","title":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03677596","title":"A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04629729","title":"FT819 in Subjects With B-cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT06742515","title":"Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03982992","title":"Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ludwig-Maximilians - University of Munich","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}